Compare Akamai Technologies, Inc. (AKAM) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs Amphastar Pharmaceuticals Inc — how do they compare? Akamai Technologies, Inc. trades at $116.89 (market cap $16.91B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Akamai Technologies, Inc. is far larger — about 19.6× Amphastar Pharmaceuticals Inc's market cap, and Akamai Technologies, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AKAM | AMPH | |
|---|---|---|
Market Cap | $16.91B | $863.95M |
Sector | Technology | Health |
52-Week High | $161.14 | $30.81 |
52-Week Low | $71.97 | $16.87 |
Enterprise Value | $22.89B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $110.54, down 6.76% over 24 hours, reflecting recent volatility despite strong Q2 2026 earnings beats. The stock shows bearish technical signals with support at $105 and resistance at $115, while fundamentals reveal revenue growth to $4.21 billion in 2025 but declining net margins to 9.51%. Analyst sentiment is mixed with a consensus price target of $152.60, and news highlights AI-driven cloud demand boosting performance.
Outlook remains cautious due to margin pressures from infrastructure investments, though AI and cybersecurity growth offer upside. Risks include competitive threats and execution challenges. Investors should weigh solid cash flow against high P/E of 40.05, with institutional hold ratings at 49.02% suggesting neutral near-term momentum.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
